− Presents Pre-clinical Data with IKARIA Platform Demonstrating Potential to Achieve Over 90% Target Knockdown with an Annual Dosing Regimen – “At OTS this year we are pleased to share research ...
- Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform - Twenty patients have been enrolled in three single-dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results